SLXN.US Silexion Therapeutics Corp

Healthcare Biotechnology USA Stocks
1.65 USD
Close of Nov 18, 2026
1.61 777.12
Market cap
USD 1.07M
P/E
-
P/B
28.93x
ROE
-396.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SLXN.US undervalued?

Graham number

The Graham number of Silexion Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Silexion Therapeutics Corp fundamental analysis

No fundamental analysis for Silexion Therapeutics Corp yet.

Silexion Therapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Silexion Therapeutics Corp

Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was foun…

Full company profile